Abstract:Therapeutic Advances in Drug Safety, Volume 15, Issue , January-December 2024. Nearly all medications carry the risk of drug-induced liver injury (DILI). Idiosyncratic reactions are rare and poorly predictable, and the mechanisms are not always well understood. Pirfenidone is an oral antifibrotic drug used to treat idiopathic pulmonary fibrosis. While elevation of liver enzymes is a common adverse reaction during therapy, it rarely leads to discontinuation or reduction of the drug. Although isolated cases of liver damage or liver failure have been reported, they are infrequent. This report presents the case of a 70-year-old woman with known idiopathic pulmonary fibrosis, depression, hypothyroidism, and hypercholesterolemia who presented at our emergency department with jaundice, anorexia, and asthenia. The patient's medication regimen included lamotrigine, simvastatin, levothyroxine, and pirfenidone, which had been introduced 6 months prior. Laboratory testing revealed elevated liver enzyme levels consistent with acute hepatocellular hepatitis. Following a medical workup, which included anamnesis, laboratory testing, iconographic investigations, and liver biopsy, we concluded that the patient had suffered from pirfenidone-induced liver injury. Pirfenidone was withdrawn, and liver tests gradually improved. The purpose of this clinical case report is to highlight this rare adverse reaction and to make clinicians aware of its assessment and management. In 2018, only one other case of severe liver failure leading to the death of the patient was reported. Early detection of potential DILI during the workup is crucial to discontinue the suspected medication promptly. Any drug-induced hepatitis must be reported for registration.Plain language summaryA case report of toxic hepatitis induced by drug (pirfenidone) in a patient with idiopathic pulmonary fibrosis• Drug-induced liver injury (DILI) is a type of hepatitis caused by medication, drugs, or even herbal and dietary supplements.• There are two types of DILI reactions: intrinsic and idiosyncratic.○ The intrinsic reaction, such as acute hepatotoxicity due to acetaminophen overdose, is easily predictable and well-known.○ The idiosyncratic reaction is more complex, unpredictable, and not well-understood. Therefore, diagnosing an idiosyncratic reaction can be challenging.• Pirfenidone is an immunosuppressive drug used to treat idiopathic pulmonary fibrosis by inhibiting collagen formation through anti-fibrotic and anti-inflammatory mechanisms.• Several adverse reactions of pirfenidone are well described, including temporary elevation of liver enzymes during treatment. This adverse reaction is mostly asymptomatic and resolves spontaneously with or without dose adjustment.• However, few cases of severe DILI due to pirfenidone have been reported, which may lead to liver dysfunction.• This paper reports on a rare idiosyncratic reaction related to pirfenidone that resulted in hepatic adverse reactions.

Pirfenidone-induced liver injury, a case report of a rare idiosyncratic reaction

Drug idiosyncrasy due to pirfenidone presenting as acute liver failure: Case report and mini‐review of the literature

Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan

Idiosyncratic drug-induced liver injury: an overview

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases

A unusual presentation of liver failure caused by Ibuprofen-sustained release capsules: A case report

Idiosyncratic drug-induced liver injury: an update on the 2007 overview

Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-World Observation on Efficacy and Safety, Focus on Patients Undergoing Antithrombotic and Anticoagulant

Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis

Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial

S4684 Rare Case of Drug-Induced Liver Injury Secondary to Benadryl Use

S4397 Drug-Induced Liver Injury Secondary to Recent Ozempic use

Pazopanib-induced severe acute liver injury: A case report

Effective Therapy of Pirfenidone in a Patient with Idiopathic Retroperitoneal Fibrosis: Report of a Case

Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases

Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study

Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review